Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

830.54USD
19 Aug 2014
Price Change (% chg)

$9.12 (+1.11%)
Prev Close
$821.42
Open
$830.54
Day's High
$830.54
Day's Low
$830.54
Volume
4
Avg. Vol
7
52-wk High
$1,079.17
52-wk Low
$750.00

BMYMP.PK

Chart for BMYMP.PK

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities... (more)

Overall

Beta: 0.40
Market Cap (Mil.): $82,878.66
Shares Outstanding (Mil.): 1,657.91
Dividend: 0.36
Yield (%): 2.88

Financials

  BMYMP.PK Industry Sector
P/E (TTM): 31.00 33.74 34.44
EPS (TTM): 1.61 -- --
ROI: 10.07 18.86 18.11
ROE: 18.10 19.48 18.84
Search Stocks

FDA approves use of Eliquis to treat leg, lung clots

- Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.

21 Aug 2014

UPDATE 1-FDA approves use of Eliquis to treat leg, lung clots

Aug 21 - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.

21 Aug 2014

FDA OKs use of Eliquis to treat leg, lung clots

Aug 21 - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.

21 Aug 2014

ConvaTec owners eye 2015 sale as buyout interest builds: sources

NEW YORK - ConvaTec's private equity owners plan to explore a sale of the medical device maker next year, even as interest from several healthcare companies in a potential $10 billion acquisition intensifies, according to people familiar with the matter.

18 Aug 2014

ConvaTec owners eye 2015 sale as buyout interest builds-sources

NEW YORK, Aug 18 - ConvaTec's private equity owners plan to explore a sale of the medical device maker next year, even as interest from several healthcare companies in a potential $10 billion acquisition intensifies, according to people familiar with the matter.

18 Aug 2014

Bristol-Myers profit tops forecasts, helped by newer drugs

- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.

24 Jul 2014

UPDATE 2-Bristol-Myers profit tops forecasts, helped by newer drugs

(Adds analyst comment, shares, details on immuno-oncology drugs)

24 Jul 2014

Bristol-Myers profit tops forecasts, helped by newer drugs

July 24 - Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.

24 Jul 2014

Bristol to seek melanoma approval for Opdivo ahead of expectations

July 10 - Bristol-Myers Squibb Co said on Thursday it plans to seek U.S. marketing approval in the third quarter for its experimental cancer immunotherapy Opdivo as a treatment for advanced melanoma, which would be months sooner than Wall Street expected.

10 Jul 2014

Bristol-Myers hepatitis C drug gets approval in Japan

July 7 - Bristol-Myers Squibb and Co said its combination drug for the treatment of hepatitis C was approved in Japan.

07 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $103.10 -0.39
Pfizer Inc. (PFE.N) $28.92 +0.10
Merck & Co., Inc. (MRK.N) $59.17 +0.32
Sanofi SA (SASY.PA) €79.43 -1.16
AstraZeneca plc (AZN.L) 4,418.00p +6.50
GlaxoSmithKline plc (GSK.L) 1,429.50p -5.00
Eli Lilly and Co (LLY.N) $62.32 +0.29

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks